Adfil 6 Mg Injection 0.6 ml (Darbepoetin alfa)

Medicine overview

Adfil 6 mg Injection 0.6 mL is listed as a pegfilgrastim injection, rather than a darbepoetin alfa product. Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF), a medicine that helps the bone marrow produce neutrophils, which are white blood cells that protect against infections. It is used in selected patients receiving chemotherapy that can significantly reduce white blood cell counts. The exact Adfil formulation, manufacturer, container and approved product labeling require further verification before this information can be treated as a complete product record.

What it is used for

Pegfilgrastim is used to reduce the risk of infection-related complications caused by low neutrophil counts following certain cancer chemotherapy treatments. It can reduce the occurrence of febrile neutropenia in appropriately selected patients. Pegfilgrastim is not a treatment for anemia and does not replace red blood cell transfusions. The exact approved uses of Adfil 6 mg Injection 0.6 mL have not been verified against its official prescribing information.

How it works

Pegfilgrastim acts on receptors in the bone marrow that regulate the development and activity of neutrophils. It stimulates the production and release of these infection-fighting white blood cells after chemotherapy suppresses normal bone marrow function. Pegfilgrastim is a modified form of filgrastim designed to remain active longer in the body. This prolonged activity supports neutrophil recovery and helps reduce the duration of chemotherapy-related neutropenia. It does not directly kill bacteria or treat an existing infection.

How it is taken

Pegfilgrastim is generally administered by subcutaneous injection under the supervision of a healthcare professional. Administration must be appropriately timed in relation to chemotherapy. The exact dose, injection device, administration instructions and timing must follow the verified product label and treating clinician's instructions. Do not administer an injection identified as darbepoetin alfa when the actual product contains pegfilgrastim. Confirm the active ingredient on the original packaging before use.

Important warnings

The stated product identity contains a clinically significant discrepancy: Adfil 6 mg/0.6 mL is listed as pegfilgrastim, whereas the supplied ingredient is darbepoetin alfa. These medicines have different purposes and must not be substituted for one another.

For pegfilgrastim, important safety concerns include serious allergic reactions, splenic enlargement or rupture, acute respiratory distress syndrome, capillary leak syndrome, glomerulonephritis, aortitis and sickle cell complications. Severe left upper abdominal or shoulder pain, breathing difficulties, facial swelling, chest discomfort or sudden deterioration require urgent medical assessment. Patients with sickle cell disorders or previous serious reactions to G-CSF medicines require particular caution. Timing around chemotherapy is important and must follow approved prescribing instructions.

Side effects and monitoring

Bone pain and discomfort in the arms or legs are common effects of pegfilgrastim. Serious complications may include splenic rupture, severe allergic reactions, respiratory distress, kidney inflammation, capillary leak syndrome and inflammatory reactions affecting the aorta.

Seek urgent medical attention for severe abdominal pain, difficulty breathing, facial or throat swelling, fainting, blood in the urine or unexplained swelling. Healthcare professionals may monitor blood counts and investigate symptoms suggesting serious complications. Fever during chemotherapy requires prompt medical assessment even when pegfilgrastim has been administered.

Storage

Refrigerated storage at 2–8°C and protection from freezing are listed for Adfil. Temperature-controlled delivery arrangements must be confirmed before dispatch.